Set-in-stone criteria will reduce risk for new biotech fund

Several boxes must be ticked off before new Danish-Swedish biotech fund Sound Bioventures is ready to invest. A high-energy team, the right development stage and an indication on the smaller side are all on the list, but medtech and diagnostic firms have been excluded, says founding partner Casper Breum.
Casper Breum, founding partner at Sound Bioventures | Photo: Casper Breum, Privatfoto
Casper Breum, founding partner at Sound Bioventures | Photo: Casper Breum, Privatfoto
by ALBERT RØNNING-ANDERSSON, translated by daniel pedersen

For many years, promising Danish life science firms and imaginative biotech entrepreneurs only had a few funds to turn to when raising capital to secure their futures: Lundbeckfonden, the Novo Nordisk Foundation and Sunstone Life Science Ventures.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
!
!
Must contain at least 6 characters
!
Must contain at least 2 characters
!
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

!
Newsletter terms

Front page now

Further reading